On Monday (NASDAQ:MNDY), H.C. Wainwright adjusted its stock price target for Tyra Biosciences (NASDAQ:TYRA), a company specializing in precision medicine oncology drugs. The firm reduced the price target to $30 from $32 while maintaining a Buy rating on the stock. The adjustment follows a review of recent clinical data and the potential of Tyra's lead compound, TYRA-300, particularly in its application to non-muscle-invasive bladder cancer (NMIBC).
The analyst at H.C. Wainwright cited recent Phase 1/2 data for TYRA-300 in metastatic urothelial carcinoma (mUC) as a basis for continued optimism. In the mUC study, the drug demonstrated a 55% partial response rate and a 27% near partial response rate at the dose range of ≥90mg.
All patients receiving doses at this level experienced tumor regression, which indicates a therapeutic benefit. The safety profile of TYRA-300 was also highlighted as encouraging, showing fewer specific toxicities compared to Johnson & Johnson's Balversa (erdafitinib) at comparable doses.
Furthermore, the analyst noted that at doses of ≤60mg, there were no discontinuations or dose reductions, and any adverse events were Grade 1-2, which are considered mild. This included a single case of elevated alanine aminotransferase (ALT), a liver enzyme, deemed inconsequential.
Comparing the efficacy of TYRA-300 to Johnson & Johnson's Balversa in NMIBC, the analyst pointed to the lower dose level's success in a separate NMIBC study, suggesting potential efficacy at lower dosages.
Looking ahead, Tyra Biosciences is set to continue optimizing dosing in mUC before proceeding to a larger Phase 2 study. Moreover, the company plans to submit an Investigational New Drug (IND) application to commence a Phase 2 trial in NMIBC and initiate a Phase 2 study in achondroplasia (ACH), with dosing expected to begin in the first quarter of 2025.
The reduction in Tyra Biosciences' price target reflects a cautious but optimistic outlook for TYRA-300's future, with the analyst reiterating the Buy rating and adjusting the price target slightly to account for recent data and anticipated developments in the drug's clinical journey.
In other recent news, Tyra Biosciences has made substantial strides in its clinical trials and financial prospects. The FDA approved the company's Phase 2 trial for its drug TYRA-300, aimed at treating achondroplasia. This trial, named BEACH301, will assess the drug's safety and its impact on annualized growth velocity.
Piper Sandler has maintained an Overweight rating on Tyra Biosciences, following the FDA's clearance, and reaffirmed a steady price target of $33.00. Furthermore, H.C. Wainwright has lifted its stock target for Tyra Biosciences, retaining a Buy rating, following encouraging data from the SURF-301 Phase 1/2 trial of TYRA-300 in metastatic urothelial carcinoma.
TD Cowen also maintained a Buy rating on the company's shares after positive preliminary results from the Triple abstract. These recent developments indicate a positive progression in the company's development pipeline.
InvestingPro Insights
Tyra Biosciences' recent clinical data and potential for TYRA-300 are reflected in its current market valuation and financial metrics. According to InvestingPro data, the company's market capitalization stands at $851.77 million, indicating significant investor interest despite its current unprofitability. This aligns with the analyst's optimistic outlook on the company's drug development progress.
InvestingPro Tips highlight that Tyra Biosciences holds more cash than debt on its balance sheet and its liquid assets exceed short-term obligations. These factors provide the company with financial flexibility to continue its clinical trials and drug development efforts, which is crucial given the capital-intensive nature of the biotechnology industry.
However, it's important to note that the company is not profitable over the last twelve months, with an adjusted operating income of -$100.07 million. This is consistent with the early-stage nature of many biotech firms focused on drug development. The stock's recent performance has been mixed, with a 36.99% return over the past year but a 26.57% decline in the last month, reflecting the volatile nature of biotech stocks as they progress through clinical trials.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for Tyra Biosciences, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.